FoldRx Pharmaceuticals Garners $29,000,000 New Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=582cabb3-5e08-43b2-acb3-f789a66fc3d1&Preview=1 -
Date
6/15/2010 -
Company Name
FoldRx Pharmaceuticals -
Mailing Address
100 Acorn Park Drive 5th Floor Cambridge, MA 02140 -
Company Description
FoldRx is a leader in the discovery and development of first in class disease modifying drug therapies for diseases of protein misfolding and amyloidosis. -
Website
http://www.foldrx.com -
Transaction Type
Venture Equity -
Transaction Amount
$29,000,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
This financing is recognition of the strength of our tafamidis program and will allow us to continue advancing the development of tafamidis. We anticipate filing marketing applications in the second half of 2010. -
M&A Terms
-
Venture Investor
Novo A/S -
Venture Investor
Morgenthaler Ventures -
Venture Investor
HealthCare Ventures -
Venture Investor
Fidelity BioSciences -
Venture Investor
TPG Biotechnology Partners -
Venture Investor
Novartis Venture Fund -
Venture Investor
Alta Partners
